Evidence map›Paper›PMID 35860380›Full record

Trial reportFrontiers in cellular and infection microbiology2022

Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial.

Lanfeng Xue, Zhiliang Deng, Wenhui Luo, Xingxiang He, Yu Chen

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 164 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
164citing papers in PubMed, 3 pooled it
20.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

164 citing papers in PubMed, 3 syntheses or guidelines pooled it, 209 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Fecal Microbiota Transplantation BeyondJournal of Korean medical science · 2026
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Sarcopenia and MASLD: novel insights and the future.Nature reviews. Endocrinology · 2026
    Review
  18. Review
  19. Review
  20. Review

104 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Lanfeng XueDepartment of Gastroenterology, The Seventh Affiliated Hospital of Southern Medical University, Foshan, China.
Zhiliang DengDepartment of Gastroenterology, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Wenhui LuoDepartment of Gastroenterology, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Xingxiang HeDepartment of Gastroenterology, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Yu ChenDepartment of Gastroenterology, The Seventh Affiliated Hospital of Southern Medical University, Foshan, China.
First Affiliated Hospital of Guangdong Pharmaceutical University · CNThird Affiliated Hospital of Southern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: The clinical efficacy of fecal microbiota transplantation (FMT) in patients with non-alcoholic fatty liver disease (NAFLD) and the variant effects of FMT on lean and obese NAFLD patients remain elusive. Our study aimed to determine the clinical efficacy and safety of FMT for patients with NAFLD, elucidating its different influences on lean and obese patients with NAFLD. Methods: We performed a randomized and controlled clinical trial. Patients in the non-FMT group were administered oral probiotics. In the FMT group, patients were randomized to receive FMT with donor stool (heterologous) Results: FMT can decrease the fat accumulation in the liver by improving the gut microbiota dysbiosis, thus attenuating fatty liver disease. Significant differences in the clinical features and gut microbiota between lean and obese NAFLD patients were unveiled. Moreover, FMT had better effects on gut microbiota reconstruction in lean NAFLD than in obese NAFLD patients. Conclusions: FMT could successfully improve the therapeutic effects on patients with NAFLD, and its clinical efficacy was higher in lean NAFLD than in obese NAFLD patients.

Indexed as

Gastrointestinal MicrobiomeNon-alcoholic Fatty Liver DiseaseDysbiosisFecal Microbiota TransplantationHumansObesityfecal microbiota transplantationgut microbiotalean NAFLDnon-alcoholic fatty liver diseaseobese NAFLD

Identifiers

PMID35860380
PMCPMC9289257
OpenAlexW4283790172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.